HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

This article was originally published in The Tan Sheet

Executive Summary

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

You may also be interested in...

Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales

Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch

Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?

Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.

Somaxon Sleep Aid Silenor Not Effective, FDA Says

In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts